(SeaPRwire) – By: Christian Brooks
Pfizer’s stock rose, but patent threats loom. Berobenatide Phase 2b data: 15% weight loss in trials. Once-monthly dose vs. weekly Wegovy, Zepbound.
Company plans over 20 trials in 2026. Cancer and vaccine pipelines active. $10.5B deal with Innovent, but Eliquis, Ibrance, Xtandi patents could cost over $20B in 2025. Debt $60.5B, dividend yield 6.7%. Pfizer walks a tightrope between new drugs and patent expirations.
Author bio: Christian Brooks, financial analyst focusing on pharma industry dynamics